Eltrombopag for treating chronic immune thrombocytopenia

Review Decision: May 2014 information

Appendix A: GE decision paper - May 2014 (PDF 168 KB)

Review Proposal: March 2014 information

Appendix A: provisional matrix of stakeholders (PDF 37 KB)

Appendix B: proposal paper presented to the Institute's Guidance Executive (PDF 384 KB)

Thrombocytopenic purpura - eltrombopag (rev TA205): equality impact assessment - guidance development (PDF 20 KB)

Thrombocytopenic purpura - eltrombopag (rev TA205): final appraisal determination information

Thrombocytopenic purpura - eltrombopag (rev TA205): final appraisal determination (PDF 224 KB)

Thrombocytopenic purpura - eltrombopag (rev TA205): evaluation report information

Thrombocytopenic purpura - eltrombopag (rev TA205): evaluation report (PDF 890 KB)

Thrombocytopenic purpura - eltrombopag (rev TA205): EIA form - scoping (PDF 15 KB)

Thrombocytopenic purpura - eltrombopag (rev TA205): appraisal consultation 2

Thrombocytopenic purpura - eltrombopag (rev TA205): appraisal consultation 2 document information

Thrombocytopenic purpura - eltrombopag (rev TA205): consultee and commentator comments on the Appraisal Consultation Document

Thrombocytopenic purpura - eltrombopag (rev TA205): GlaxoSmithKline (PDF 114 KB)

Thrombocytopenic purpura - eltrombopag (rev TA205): ITP Support Association (PDF 28 KB)

Thrombocytopenic purpura - eltrombopag (rev TA205): Royal College of Nurses (PDF 63 KB)

Thrombocytopenic purpura - eltrombopag (rev TA205): Amgen (PDF 196 KB)

Thrombocytopenic purpura - eltrombopag (rev TA205): comments on the Appraisal Consultation Document received through the NICE website (PDF 20 KB)

Thrombocytopenic purpura - eltrombopag (rev TA205): ERG review of responses to the ACD related to assumptions in the economic modelling prepared by the Evidence Review Group, Aberdeen HTA (PDF 150 KB)

Thrombocytopenic purpura - eltrombopag (rev TA205): appraisal consultation

Thrombocytopenic purpura - eltrombopag (rev TA205): appraisal consultation document information

Thrombocytopenic purpura - eltrombopag (rev TA205): Evaluation report

Thrombocytopenic purpura - eltrombopag (rev TA205): Pre-meeting briefing (PDF 268 KB)

Thrombocytopenic purpura - eltrombopag (rev TA205): Evidence Review Group report (PDF 1.52 MB)

Thrombocytopenic purpura - eltrombopag (rev TA205): GlaxoSmithKline (PDF 2.84 MB)

Thrombocytopenic purpura - eltrombopag (rev TA205): Clarification

Thrombocytopenic purpura - eltrombopag (rev TA205): NICE clarification Letter (PDF 80 KB)

Thrombocytopenic purpura - eltrombopag (rev TA205): Manufacturer response to the NICE clarification letter (PDF 212 KB)

Thrombocytopenic purpura - eltrombopag (rev TA205): ITP Support Association (PDF 641 KB)

Thrombocytopenic purpura - eltrombopag (rev TA205): Expert written personal statements

Thrombocytopenic purpura - eltrombopag (rev TA205): Allen (PDF 73 KB)

Thrombocytopenic purpura - eltrombopag (rev TA205): Cooper (PDF 57 KB)

Thrombocytopenic purpura - eltrombopag (rev TA205): Watson (PDF 57 KB)

Thrombocytopenic purpura - eltrombopag (rev TA205): Wimperis (PDF 58 KB)

Thrombocytopenic purpura - eltrombopag (rev TA205): final scope (PDF 48 KB)

Thrombocytopenic purpura - eltrombopag (rev TA205): response to consultee and commentator comments on the draft remit and draft scope (PDF 116 KB)

Thrombocytopenic purpura - eltrombopag (rev TA205): final matrix (PDF 49 KB)

Thrombocytopenic purpura - eltrombopag (rev TA205): provisional matrix (PDF 25 KB)

Thrombocytopenic purpura - eltrombopag (rev TA205): draft scope (PDF 27 KB)